Dudediligence.

Roivant Sciences Ltd

ROIVNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$4.5MSep ’24$9.0MDec ’24$7.6MMar ’25$2.2MJun ’25$1.6MSep ’25$2.0MDec ’25$2.5MMar ’26$1.4MJun ’26
Net income, by quarter
−$230.2MSep ’24$169.4MDec ’24−$206.5MMar ’25−$223.4MJun ’25−$113.5MSep ’25−$265.9MDec ’25$303.0MMar ’26−$189.8MJun ’26
Fiscal years, by the month each ended
LineMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue$55.3M$31.5M$32.7M$29.1M$8.3M
Operating income−$1.35B−$906.8M$4.50B−$1.00B−$515.1M
Net income−$845.3M−$1.01B$4.35B−$172.0M−$299.8M
Operating cash flow−$677.7M−$843.4M−$765.3M−$839.5M−$750.3M
Free cash flow−$695.2M−$856.1M−$766.6M−$844.0M−$758.6M
Cash$2.06B$1.68B$6.49B$2.72B$1.42B
Debt$210.0M$416.2M$442.6Mnone on filenone on file
Shares outstanding695.0M760.1M806.7M695.9M720.4M